Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB)

Q: What does CUSIP 984241109 represent in this 13F holders report?

CUSIP 984241109 is the security identifier for YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share in Q4 2020?

115 institutional investors reported YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share for Q4 2020. Use the holders table for investor-level position and value details.

CUSIP: 984241109

Q4 2020 13F Holders as of 31 Dec 2020

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 45,101,565
Total 13F shares: 22,809,127
Share change: +753,680
Total reported value: $1,129,308,254
Price per share: $49.51
Number of holders: 115
Value change: +$38,442,838
Number of buys: 59
Number of sells: 40

Quarterly Holders Quick Answers

What is CUSIP 984241109?
CUSIP 984241109 identifies YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2021
Previous quarter: Q3 2020

Recent filing periods for CUSIP 984241109:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) as of Q4 2020

As of 31 Dec 2020, Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) was held by 115 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 22,809,127 shares. The largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., Sofinnova Investments, Inc., Cormorant Asset Management, LP, VANGUARD GROUP INC, Artisan Partners Limited Partnership, ALLIANCEBERNSTEIN L.P., FMR LLC, STATE STREET CORP, and GOLDMAN SACHS GROUP INC. This page lists 115 institutional shareholders reporting positions in this security for the Q4 2020 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2020 vs Q3 2020 Across Filers

Q3 2020 holders

105

Q4 2020 holders

115

Holder diff

Investor	Q3 2020 Shares	Q4 2020 Shares	Share Diff	Share Chg %	Q3 2020 Value $	Q4 2020 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.